Across TCGA pan-cancer cohorts, FBXO32 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FBXO32 data layer compared with 24 for mass-spec protein and 2 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FBXO32 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated FBXO32 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, PRAD, and HNSC are the cancer types where FBXO32 Mutation most reproducibly stratifies survival.